Beauty Health (SKIN)
(Delayed Data from NSDQ)
$1.60 USD
-0.06 (-3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.60 USD
-0.06 (-3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Compared to Estimates, Beauty Health (SKIN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Beauty Health (SKIN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -103.70% and 0.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
by Zacks Equity Research
The headline numbers for Beauty Health (SKIN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 28.57% and 1.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -2.52% and 3%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, The Beauty Health Company (SKIN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for The Beauty Health Company (SKIN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 14.29% and 10.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Beauty Health Company (SKIN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 11.54% and 0.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Does The Beauty Health Company (SKIN) Have the Potential to Rally 122.94% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for The Beauty Health Company (SKIN) points to a 122.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 40% and 0.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Implied Volatility Surging for Beauty Health (SKIN) Stock OptionsInvestors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of -100% and 3.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
The Beauty Health Company (SKIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Q4 Earnings Meet Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 0% and 3.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Beauty Health (SKIN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
Elevance Health (ELV) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.06% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.